Clinical trials tracker
Registry-aware watchpoints for longevity-relevant human studies. Trial registration is evidence of a question, not proof of an answer.
Longevity drugs
| Item | Claims | Status | Evidence / risk | Source |
|---|---|---|---|---|
| Rapamycin / sirolimus aging studies Checked 2026-06-27 Related briefing | mTOR modulation, immune aging, biological age | Check each registry entry for status and endpoints | Evidence:Trial registeredRisk:High riskStatus:Off-label Human trials are important but vary widely in design, population and outcome strength. Prescription-drug adverse effects, infection risk, monitoring burden. | ClinicalTrials.gov |
| Metformin aging-related trials Checked 2026-06-27 Related briefing | geroscience, multimorbidity delay, metabolic resilience | Approved for other uses; aging endpoints remain under study | Evidence:Trial registeredRisk:Moderate riskStatus:Approved for another use The key question is whether metformin affects aging-related outcomes beyond diabetes treatment. Medication interactions, kidney considerations, inappropriate use. | ClinicalTrials.gov |
Senolytics
| Item | Claims | Status | Evidence / risk | Source |
|---|---|---|---|---|
| Senolytic trials Checked 2026-06-27 Related briefing | senescent-cell reduction, frailty, tissue function | Disease- and trial-specific; not broad consumer use | Evidence:Trial registeredRisk:High riskStatus:Experimental Human work is emerging, but consumer longevity claims remain ahead of outcomes. Drug toxicity, inappropriate combinations, weak biomarker interpretation. | ClinicalTrials.gov |